INSYS Therapeutics, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company reported net revenue of 91,135,000 against $66,512,000 a year ago. Income from operations was $29,721,000 against $16,146,000 a year ago. Income before income taxes was $29,907,000 against $16,211,000 reported last year. Net income was $17,011,000 or $0.22 per diluted share compared to $9,349,000 or $0.13 per diluted share for the fourth quarter of 2014. EBITDA was $31,231,000 against $16,935,000 and adjusted EBITDA was $39,346,000 against $21,001,000 reported last year. Non-GAAP adjusted net income was $27.2 million, or $0.36 per diluted share, compared to $19.5 million, or $0.26 per diluted share, in the prior year quarter. Adjusted income before income taxes was $38,022,000 against $20,277,000 reported last year.

For the year, the company reported net revenue of 330,797,000 against $222,125,000 a year ago. Income from operations was $92,430,000 against $64,023,000 a year ago. Income before income taxes was $92,968,000 against $64,176,000 reported last year. Net income was $58,476,000 or $0.77 per diluted share compared to $64,176,000 or $0.52 per diluted share a year ago. EBITDA was $97,757,000 against $66,525,000 and adjusted EBITDA was $127,654,000 against $81,814,000 reported last year. Non-GAAP adjusted net income, which adjusts for non-cash stock compensation expense and non-cash income tax expense, was $104.2 million, or $1.38 per diluted share, compared to $78.7 million, or $1.07 per diluted share, in the prior year. Adjusted income before income taxes was $122,865,000 against $79,465,000 reported last year. The company continue to generate positive cash flow with cash, cash equivalents and short and long-term investments in excess of $202 million as of December 31, 2015.

The company announced able to get a tax rate down to maybe to 33% to 35% range for 2016.